chevron_leftBack
V
As of 15 June 2026, Viskase Holdings, Inc. has a market cap of $85.99M USD, ranking #26615 globally and #4062 in the United States.
It ranks #2384 in the Healthcare sector, and #857 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$85.99MUSD
Enterprise Value
$88.02MUSD
Net Income (TTM)
-$5.53MUSD
PB Ratio
2.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Thomas Davis
open_in_new
Employees
1
Founded
1981
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.7% | 5.3% | -8.5% | -11% | 5.5% | -33% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ENZN
ISIN: US2939048011
Shares Out.:
Shares Outstanding:
14.332M1
Shares Float:
887.398K2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
5.90 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Viskase Holdings, Inc.
Viskase Holdings, Inc. focuses on non-edible cellulosic, fibrous, and plastic casings used to prepare and package processed meat and poultry products. The company was formerly known as Enzon Pharmaceuticals, Inc. and changed its name to Viskase Holdings, Inc. in March 2026. Viskase Holdings, Inc. was incorporated in 1981 and is headquartered in Lombard, Illinois. As of March 26, 2026, Viskase Holdings, Inc. operates as a subsidiary of Viskase Companies, Inc.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
886K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
636K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
419K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
319K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
174K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
137K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
374K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
336K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
319K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
211K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
128K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
126K%
80.96B GBP
|
14.6
|
chevron_leftBack